Here's I post I thought wes worthy of posting here, a sensible post refuting some of Goldseekers claims by someone in the industry, for those of you that didn't read it:

Took some time to catch up on posts over the last few weeks - lots of opinions.

My observations:

I was frustrated with this stock when Abbott was the big hope. They did nothing with it, no progress was made. Even though the stock price is down a lot, IMO bocx is now doing the right things scientifically and business-wise (elisa). And the company's PRs are clearly communicating this.

The fixation by the 4 amigos on Abbott is neurotic. Abbott is doing exactly what you would expect them to do. They negotiated a placeholder licensing agreement that will allow them to exploit the technology when it is ready for market. But it is not their role to develop the product. Biocurex has to do that. I think some folks are spending an unhealthy amount of time parsing and re-parsing PRs re Abbott.

I think the biggest source of error on this board is lack of understanding of how the scientific process works. You don't present a poster at ISOBM and suddenly have your product adopted by the medical community. There have to be controlled clinical trials and publications in mainstream journals before it will be accepted. Getting the product out to labs via elisa is the first step.

In post 15640, GS suggests that Abbott's reason for modifying the license agreement was because the science doesn't work, at least doesn't work well enough for commercialization. GS puts forward this view repeatedly as if it were fact, but in fact it is completely baseless. It was most likely a commercial decision that had nothing to do with science.

Similarly, the constant assertions that bocx tests are worthless unless they also (a) allow you to identify the location of the cancer, and (b) facilitate therapy, are complete non-sense. I am a scientist (not MD) working in cancer therapy. If you read any comprehensive cancer text, it will identify the ability to detect cancer early as the main factor that will improve treatment outcomes going forward. The facts suggest that bocx products will have a huge market if they can negotiate their way through to clinical trials and commercialization.

QB